Zacks1d agoneutral
Can Volume Growth and RPT Recovery Support DaVita's Q2 Earnings?DVA's Q2 results are likely to benefit from volume growth and RPT recovery, but payor mix pressure and spending on technology could limit margin gains.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
536last 24h
2518last 7d
483● bullish (7d)
258● bearish (7d)
197publishers
StockStory2d agoneutral
DaVita (DVA) Reports Q2: Everything You Need To Know Ahead Of EarningsDialysis provider DaVita Inc. (NYSE:DVA) will be reporting earnings this Tuesday afternoon. Here’s what you need to know.
Zacks5d agobullish
Is DGX Stock Worth Buying After Its Strong 2026 Earnings Momentum?Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but valuation, debt and margin pressure temper the buy case.
StockStory7d agoneutral
DaVita (DVA): Buy, Sell, or Hold Post Q1 Earnings?What a time it’s been for DaVita. In the past six months alone, the company’s stock price has increased by a massive 122%, reaching $235.17 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Barchart21d agoneutral
What You Need To Know Ahead of DaVita’s Earnings ReleaseDaVita is entering earnings with strong momentum as investors look for another quarter of solid execution.
Simply Wall St.60d agobullish
Assessing DaVita (DVA) Valuation After Strong Q1 2026 Beat And Upgraded GuidanceDaVita (DVA) is back in focus after first quarter 2026 revenue and earnings surpassed analysts' expectations, prompting management to lift full year guidance and drawing fresh attention from investors and research desks. See our latest analysis for DaVita. The strong first quarter has come after a powerful run in the stock, with the share price up 27.46% over 90 days and a 67.81% year to date share price return. The 3 year total shareholder return of 97.13% suggests longer term holders have...
StockStory61d agoneutral
Q1 Earnings Highs And Lows: DaVita (NYSE:DVA) Vs The Rest Of The Outpatient & Specialty Care StocksAs the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at outpatient & specialty care stocks, starting with DaVita (NYSE:DVA).
Zacks62d agoneutral
DaVita HealthCare (DVA) Up 0.6% Since Last Earnings Report: Can It Continue?DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
StockStory82d agoneutral
The 5 Most Interesting Analyst Questions From DaVita’s Q1 Earnings CallDaVita’s first quarter results were met with a strongly positive market reaction, reflecting operational execution and ongoing cost control. Management attributed the quarter’s outperformance to balanced gains across treatment volume, revenue per treatment, and cost management, aided by productivity improvements and favorable patient outcomes. CEO Javier Rodriguez highlighted the continued momentum of the company’s Integrated Kidney Care (IKC) business, which delivered year-over-year improvement
Zacks85d agobearish
Hims & Hers Stock Plunges Post Q1 Earnings Miss, Gross Margin DownHIMS reports an adjusted loss and a revenue miss in first-quarter 2026 as gross margin decreases, but it lifts its full-year revenue outlook.